Chemotherapy use in stage III colon cancer: A National Cancer Database analysis

Smrity Upadhyay, Sumit Dahal, Vijaya R Bhatt, Nabin Khanal, Peter T. Silberstein

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Although adjuvant chemotherapy in stage III colon cancer improves overall survival, prior studies have shown that it is underused. We analyzed different factors that may influence its use. Methods: This is a retrospective study of stage III colon cancer patients (n = 207,718) diagnosed between 2000 and 2011 in the National Cancer Data Base (NCDB). The NCDB contains ~70% of new cancer diagnosis from >1500 American College of Surgeons accredited cancer programs in the United States and Puerto Rico. The chi-squared test was used to determine any difference in characteristics of patients who did or did not receive chemotherapy. Results: A total of 35% of all stage III colon cancer patients, and 38% of stage III cases undergoing surgery, did not receive adjuvant chemotherapy. The use of chemotherapy had increased in recent years (64% in 2007–2011 versus 59% in 2000–2002; p < 0.0001). Its use was lower in whites (61%), females (60%), patients ⩾60 years (55%), patients with one or more comorbidities (55%), nonacademic centers (62%), those with medicare insurance (52%), lower education (61%) and income levels (59%, all p < 0.0001). The nonwhite and uninsured were more likely to be <60 years old. More than one-third did not receive adjuvant chemotherapy, although its use has increased in more recent years. Age was one of the most important determinants of chemotherapy use, which may explain higher rates in nonwhite and uninsured. In addition to patient characteristics, race, gender and socioeconomic factors influence chemotherapy use. These findings have important implications for healthcare reform.

Original languageEnglish (US)
Pages (from-to)244-251
Number of pages8
JournalTherapeutic Advances in Medical Oncology
Volume7
Issue number5
DOIs
StatePublished - Sep 2015

Fingerprint

Colonic Neoplasms
Databases
Drug Therapy
Adjuvant Chemotherapy
Neoplasms
Puerto Rico
Health Care Reform
Medicare
Insurance
Comorbidity
Retrospective Studies
Education
Survival

Keywords

  • Chemotherapy
  • Disparities
  • Stage III colon cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Chemotherapy use in stage III colon cancer : A National Cancer Database analysis. / Upadhyay, Smrity; Dahal, Sumit; Bhatt, Vijaya R; Khanal, Nabin; Silberstein, Peter T.

In: Therapeutic Advances in Medical Oncology, Vol. 7, No. 5, 09.2015, p. 244-251.

Research output: Contribution to journalArticle

Upadhyay, Smrity ; Dahal, Sumit ; Bhatt, Vijaya R ; Khanal, Nabin ; Silberstein, Peter T. / Chemotherapy use in stage III colon cancer : A National Cancer Database analysis. In: Therapeutic Advances in Medical Oncology. 2015 ; Vol. 7, No. 5. pp. 244-251.
@article{5d6ab9d381e74649b3ec8656a5836220,
title = "Chemotherapy use in stage III colon cancer: A National Cancer Database analysis",
abstract = "Background: Although adjuvant chemotherapy in stage III colon cancer improves overall survival, prior studies have shown that it is underused. We analyzed different factors that may influence its use. Methods: This is a retrospective study of stage III colon cancer patients (n = 207,718) diagnosed between 2000 and 2011 in the National Cancer Data Base (NCDB). The NCDB contains ~70{\%} of new cancer diagnosis from >1500 American College of Surgeons accredited cancer programs in the United States and Puerto Rico. The chi-squared test was used to determine any difference in characteristics of patients who did or did not receive chemotherapy. Results: A total of 35{\%} of all stage III colon cancer patients, and 38{\%} of stage III cases undergoing surgery, did not receive adjuvant chemotherapy. The use of chemotherapy had increased in recent years (64{\%} in 2007–2011 versus 59{\%} in 2000–2002; p < 0.0001). Its use was lower in whites (61{\%}), females (60{\%}), patients ⩾60 years (55{\%}), patients with one or more comorbidities (55{\%}), nonacademic centers (62{\%}), those with medicare insurance (52{\%}), lower education (61{\%}) and income levels (59{\%}, all p < 0.0001). The nonwhite and uninsured were more likely to be <60 years old. More than one-third did not receive adjuvant chemotherapy, although its use has increased in more recent years. Age was one of the most important determinants of chemotherapy use, which may explain higher rates in nonwhite and uninsured. In addition to patient characteristics, race, gender and socioeconomic factors influence chemotherapy use. These findings have important implications for healthcare reform.",
keywords = "Chemotherapy, Disparities, Stage III colon cancer",
author = "Smrity Upadhyay and Sumit Dahal and Bhatt, {Vijaya R} and Nabin Khanal and Silberstein, {Peter T.}",
year = "2015",
month = "9",
doi = "10.1177/1758834015587867",
language = "English (US)",
volume = "7",
pages = "244--251",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Chemotherapy use in stage III colon cancer

T2 - A National Cancer Database analysis

AU - Upadhyay, Smrity

AU - Dahal, Sumit

AU - Bhatt, Vijaya R

AU - Khanal, Nabin

AU - Silberstein, Peter T.

PY - 2015/9

Y1 - 2015/9

N2 - Background: Although adjuvant chemotherapy in stage III colon cancer improves overall survival, prior studies have shown that it is underused. We analyzed different factors that may influence its use. Methods: This is a retrospective study of stage III colon cancer patients (n = 207,718) diagnosed between 2000 and 2011 in the National Cancer Data Base (NCDB). The NCDB contains ~70% of new cancer diagnosis from >1500 American College of Surgeons accredited cancer programs in the United States and Puerto Rico. The chi-squared test was used to determine any difference in characteristics of patients who did or did not receive chemotherapy. Results: A total of 35% of all stage III colon cancer patients, and 38% of stage III cases undergoing surgery, did not receive adjuvant chemotherapy. The use of chemotherapy had increased in recent years (64% in 2007–2011 versus 59% in 2000–2002; p < 0.0001). Its use was lower in whites (61%), females (60%), patients ⩾60 years (55%), patients with one or more comorbidities (55%), nonacademic centers (62%), those with medicare insurance (52%), lower education (61%) and income levels (59%, all p < 0.0001). The nonwhite and uninsured were more likely to be <60 years old. More than one-third did not receive adjuvant chemotherapy, although its use has increased in more recent years. Age was one of the most important determinants of chemotherapy use, which may explain higher rates in nonwhite and uninsured. In addition to patient characteristics, race, gender and socioeconomic factors influence chemotherapy use. These findings have important implications for healthcare reform.

AB - Background: Although adjuvant chemotherapy in stage III colon cancer improves overall survival, prior studies have shown that it is underused. We analyzed different factors that may influence its use. Methods: This is a retrospective study of stage III colon cancer patients (n = 207,718) diagnosed between 2000 and 2011 in the National Cancer Data Base (NCDB). The NCDB contains ~70% of new cancer diagnosis from >1500 American College of Surgeons accredited cancer programs in the United States and Puerto Rico. The chi-squared test was used to determine any difference in characteristics of patients who did or did not receive chemotherapy. Results: A total of 35% of all stage III colon cancer patients, and 38% of stage III cases undergoing surgery, did not receive adjuvant chemotherapy. The use of chemotherapy had increased in recent years (64% in 2007–2011 versus 59% in 2000–2002; p < 0.0001). Its use was lower in whites (61%), females (60%), patients ⩾60 years (55%), patients with one or more comorbidities (55%), nonacademic centers (62%), those with medicare insurance (52%), lower education (61%) and income levels (59%, all p < 0.0001). The nonwhite and uninsured were more likely to be <60 years old. More than one-third did not receive adjuvant chemotherapy, although its use has increased in more recent years. Age was one of the most important determinants of chemotherapy use, which may explain higher rates in nonwhite and uninsured. In addition to patient characteristics, race, gender and socioeconomic factors influence chemotherapy use. These findings have important implications for healthcare reform.

KW - Chemotherapy

KW - Disparities

KW - Stage III colon cancer

UR - http://www.scopus.com/inward/record.url?scp=84940191842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940191842&partnerID=8YFLogxK

U2 - 10.1177/1758834015587867

DO - 10.1177/1758834015587867

M3 - Article

C2 - 26327922

AN - SCOPUS:84940191842

VL - 7

SP - 244

EP - 251

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 5

ER -